CD1-HM455-100μg / 询价

CD1-HM455-500μg / 询价

CD1-HM455-1mg / 询价

Human CD155/PVR Protein

产品信息(Product Info)

Recombinant Human CD155/PVR Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Trp21-Asn343.[Accession | P15151-1]

分子量大小(Molecular Weight)

The protein has a predicted MW of 38 kDa. Due to glycosylation, the protein migrates to 55-70 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by SEC-HPLC


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.


Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.


-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Human CD155 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.


The purity of Human CD155 is greater than 95% as determined by SEC-HPLC.


Immobilized Human CD155, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Human TIGIT, hFc Tag with the EC50 0.5μg/ml determined by ELISA.


CD155 is a cell surface adhesion molecule functioning in tumor cell migration, invasion, and metastasis, and not surprisingly, is also designated as a common tumor-associated antigen. CD155 is also recognized by NK cells to induce their cytotoxicity. CD155 is also commonly referred to as the "poliovirus receptor," or PVR.


CD155; HVED; NECL5; Necl-5; nectin-like 5; PVR; PVS; Tage4; PVSFLJ25946; FLJ25946


(1)Yu X , Harden K , C Gonzalez L , et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells[J]. NATURE IMMUNOLOGY, 2008, 10(1):48-57.